Hims & Hers Health (NYSE:HIMS) Upgraded at Wall Street Zen
by Jessica Moore · The Cerbat GemWall Street Zen upgraded shares of Hims & Hers Health (NYSE:HIMS – Free Report) from a sell rating to a hold rating in a report released on Saturday.
A number of other research firms also recently issued reports on HIMS. Weiss Ratings reiterated a “hold (c)” rating on shares of Hims & Hers Health in a research report on Friday, March 27th. BTIG Research downgraded shares of Hims & Hers Health from a “buy” rating to a “neutral” rating in a research note on Tuesday, February 24th. Morgan Stanley dropped their price objective on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating on the stock in a report on Tuesday, February 24th. Truist Financial reissued a “hold” rating and set a $18.00 price objective (down from $37.00) on shares of Hims & Hers Health in a research report on Tuesday, February 24th. Finally, Bank of America upgraded Hims & Hers Health from an “underperform” rating to a “neutral” rating and raised their target price for the company from $12.50 to $23.00 in a research note on Tuesday, March 10th. Three research analysts have rated the stock with a Buy rating, thirteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $31.71.
Check Out Our Latest Analysis on HIMS
Hims & Hers Health Trading Up 9.1%
NYSE HIMS opened at $21.19 on Friday. The stock has a market capitalization of $4.83 billion, a P/E ratio of 41.55, a P/E/G ratio of 1.85 and a beta of 2.32. The business has a 50 day simple moving average of $19.61 and a 200 day simple moving average of $33.02. The company has a debt-to-equity ratio of 1.80, a current ratio of 1.90 and a quick ratio of 1.70. Hims & Hers Health has a one year low of $13.74 and a one year high of $70.43.
Hims & Hers Health (NYSE:HIMS – Get Free Report) last issued its quarterly earnings results on Monday, February 23rd. The company reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.06. The firm had revenue of $617.82 million for the quarter, compared to analyst estimates of $619.48 million. Hims & Hers Health had a return on equity of 22.48% and a net margin of 5.47%.The company’s revenue was up 28.4% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.11 earnings per share. Research analysts expect that Hims & Hers Health will post 0.29 earnings per share for the current year.
Insider Buying and Selling at Hims & Hers Health
In other Hims & Hers Health news, insider Irene Becklund sold 5,529 shares of the business’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $136,511.01. Following the completion of the sale, the insider owned 8,752 shares in the company, valued at approximately $216,086.88. The trade was a 38.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Soleil Boughton sold 4,812 shares of the firm’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total transaction of $118,808.28. Following the completion of the transaction, the insider directly owned 308,831 shares in the company, valued at $7,625,037.39. This trade represents a 1.53% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 129,889 shares of company stock worth $3,230,986. Company insiders own 17.71% of the company’s stock.
Hedge Funds Weigh In On Hims & Hers Health
A number of hedge funds have recently added to or reduced their stakes in HIMS. Hsbc Holdings PLC increased its holdings in Hims & Hers Health by 427.1% during the 4th quarter. Hsbc Holdings PLC now owns 33,582 shares of the company’s stock worth $1,090,000 after purchasing an additional 27,211 shares in the last quarter. Rockefeller Capital Management L.P. lifted its holdings in shares of Hims & Hers Health by 13.8% in the fourth quarter. Rockefeller Capital Management L.P. now owns 41,088 shares of the company’s stock valued at $1,334,000 after purchasing an additional 4,980 shares in the last quarter. Gunpowder Capital Management LLC dba Oliver Wealth Management bought a new position in shares of Hims & Hers Health in the fourth quarter valued at approximately $80,000. SHP Wealth Management purchased a new position in shares of Hims & Hers Health during the fourth quarter valued at approximately $106,000. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Hims & Hers Health by 413.5% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 17,228 shares of the company’s stock worth $559,000 after buying an additional 13,873 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.
About Hims & Hers Health
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.